Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Debio-0123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Debio-0123 overview
Debio-0123 (ADC-730) is under development for the treatment of advanced solid tumors. The drug candidate is administered orally as a capsule. It acts by targeting WEE-1, a nuclear protein kinase. It was also under development for the treatment of colon and lung adenocarcinoma.
Debiopharm International overview
Debiopharm International, a subsidiary of Debiopharm Group, focuses on development and manufacture of drugs for oncology and bacterial infections. The company offers Oxaliplatin and Triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections, and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.
For a complete picture of Debio-0123’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
